Abgent is a biological reagents and custom services company located in Oxfordshire and headquartered in San Diego, CA. Our goal is to provide high quality, low cost products and services to support groundbreaking scientific research across the globe.
Abgent pride our customer services by consulting with you at critical project junctures and offer free lifetime technical support. We also offer a no-product/no-fee service so if we take your project on but don’t complete it there will be no cost to you. We manufacture our products to GLP / GMP standard and provide customisation to meet every need. We guarantee confidentially at all times and are ISO9001 Certified.

Alacrita provides expertise-based consulting services to the biotechnology, pharmaceutical and healthcare industries. Unlike many consulting firms, all of Alacrita’s consultants are considered experts in their particular field after spending a significant portion of their careers in industry.

Alacrita conducts two types of consulting. The first is embedding a consultant within a client’s management team to fill a specific gap in expertise. The client tends to be a biotech company operating a virtual or semi-virtual model and the area of expertise may be preclinical development, clinical development, manufacturing or regulatory affairs.

The second is assembling multi-disciplinary teams to execute specific consulting projects. Such projects span a range of activities but are generally centred around either a strategic or analytical theme. Real life examples range from advising a government on implementing a streamlined biotech regulatory framework through to crafting drug development plans to underpin a financing event.

Alacrita’s continued engagement with hands-on drug development allows us to deliver project-based consulting that is rooted in the real world. Without coal-face experience, such exercises become theoretical and struggle to be translated into industrial reality.

Almac is a financially stable, privately owned organisation with over 30 years experience. The Group provides integrated development solutions to over 600 customers worldwide including all the world leaders in the pharmaceutical and biotechnology sectors.
The company has over 2,800 employees and is headquartered in Craigavon, Northern Ireland; US operations are based in Pennsylvania, North Carolina and California. Each customer is guaranteed a dedicated hands-on project management service to meet individual needs ensuring clients will experience continued success in all their ventures.
Almac provides a seamless, fast and efficient route from drug discovery through to market. Our range of services includes:

Research: Almac is focused on the delivery of biomarker solutions and supporting biomarker strategy for drug development, which underpins the delivery of personalised medicine.
Chemical & Pharmaceutical Development: Almac accelerates the development of customers’ drug candidates through the effective integration of science and manufacturing to provide drug substance & product.
Clinical Development: Almac is unique in the industry, offering fully integrated world class clinical trial supplies & IVR/IWR technology.
Commercial: Almac provides solid dosage form commercial manufacture and packaging for EU & US markets. Commercial support services facilitate EU market access for non-EU product.

Aptuscan is a biotechnology company with a focus on stratified medicine. The company owns a platform technology exploitable both in the diagnostic and the therapeutic market. This platform technology is a novel scaffold protein that can be engineered to bind to protein targets, and is a compelling alternative to full antibodies, antibody domains and other scaffolds.

The BIA is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; large pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector.

The BIA works to further the interests of members and the industry – nationally, regionally and internationally. Our heritage of innovation, enterprise and success dates back to the organisation’s founding in 1989 at the infancy of biotechnology.

BioPartner.co.uk is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Lifescience companies. BioPartner’s UK Delegations promote the UK presence at major international biopharma conferences. Through the BioPartnership Programme, BioPartner assists SMEs to attend these events by providing access to government grants and heavily discounted entry fees.

cddi is an international biotechnology and pharmaceutical consulting company, led by a full time core management team of senior people who have developed more than 30 products globally from discovery to market. Our Managing Partners personally direct a global network of people that cover a wide range of drug development expertise with skills to operate in all project areas. Since formation, we have worked with both large pharma and small biotechs, as well as with investment companies.

cddi’s Managing Partners and our people focus on operational management as well as strategic direction. Unlike a traditional consultancy who talk and advise, our mode of working is hands-on and delivery focused. With our extensive industry experience and the expertise of our people, we will achieve your specific objectives faster and more cost-effectively.

Critical Pharmaceuticals is a Nottingham UK-based biotechnology company developing a pipeline of unique biological drug products utilizing its proprietary technologies for the delivery of high value biological therapeutics and small molecule drugs. Biologics have a market of $80 billion and represent over 30% of all new drug applications. However, biologics are labile, clear rapidly from the blood circulation and often need to be administered by frequent injections that are strongly disliked by patients. Critical Pharmaceuticals has developed two unique drug delivery technologies to reduce the need for frequent injections and allow the administration by non-invasive routes. The technologies are used both in partnership with originating biopharmaceutical companies and through the development of an in-house pipeline of high-value unique biological products. The technologies have been proven in preclinical proof of concept studies, further validated by six revenue-generating collaborations with biopharmaceutical companies, a multi-program development and license option agreement with a leading life-science investor and £1.5 million funding from the Wellcome Trust to further develop its lead product. Critical Pharmaceuticals lead product is a nasal formulation of human growth hormone in Phase 1 clinical development that will have significant advantages over existing daily injectable products.

Cyprotex Discovery Limited is the world’s largest contract research organisation specialising in preclinical ADMET services to research scientists engaged in drug discovery and development. We provide support for a wide range of experimental and computational ADMET and PK services extending from early drug discovery through to IND submission.

Cyprotex core capabilities include our unique high throughput ADME screening service which is based on state of the art robotics and a highly sophisticated customised information management system. This dramatically reduces the cost and time involved in generating data whilst ensuring excellent reproducibility of data. Our customised experimental service provides support for later stage ADME and Pharmacokinetic studies specific to customer requirements. Our in silico ADME predictive modelling service provides a range of novel predictive technologies. Cyprotex’s proprietary software product Cloe® PK integrates core ADME and physicochemical properties to predict whole body pharmacokinetics and is available on our secure web portal, Cloe® Gateway.

Toxicity is the key reason for drug attrition. Our in vitro toxicology service assists customers in understanding the toxic liability of their compounds using a panel of different techniques. Cyprotex is the only contract research organisation with a proprietary High Content Toxicology platform. The CellCiphr™ technology, acquired from Cellumen, applies High Content Screening (HCS) technology to cellular models of disease and toxicity. This technology uses a proprietary advanced informatics and data interpretation platform to assess cytotoxicity to improve prediction of in vivo toxicity. The CellCiphr™ technology is an extensively validated approach that was co-developed with the participation of eight external pharmaceutical and government partners. The CellCiphr™ toxicity profiling panels can reliably identify toxic compounds before entering further preclinical testing.

Domainex has an internal pipeline of oncology targets which is based upon our unique technology Combinatorial Domain Hunting. These internal programmes are exclusively focused on nucleotide triphosphate binding domains (NTP domains) which are found in several important therapeutic targets of particular relevance to oncology. The current portfolio includes a number of lysine methyl transferases and a kinase IKK epsilon. Our IKK program is in lead optimisation. Domainex also offers services to Pharma using our unique patented technology called Combinatorial Domain Hunting (CDH) designed to rapidly express target proteins of all types including those which are technically challenging. We can also rapidly find novel robust hit like molecules with our platform technology LeadBuilder and then develop hits using highly experienced medicinal chemistry.

Eagle Genomics Ltd. is a leading bioinformatics software company based in Cambridge UK at the heart of Europe’s largest Biotech cluster. Eagle bridges the gap between academia and industry by providing packaged, ready-to-use state-of-the art, open bioinformatics for genomic data management and integration. It can also augment the capability and capacity of existing Bioinformatics departments by providing outsourced services. Eagle’s global clients include multinational Pharmaceutical organisations as well as Biotech SMEs to which they provide installation, customisation, integration, support and training services for a range of open-source bioinformatics tools and databases, including Ensembl®, Taverna.

Eden Biodesign is a globally-integrated biopharmaceutical and vaccine contract manufacturing company offering strategic consultancy, biopharmaceutical design and cGMP manufacturing services. We have a long history of successfully completed commercial assignments for clients in Europe, North America, Asia, Africa, Australasia and Latin America. Our client base ranges from biotech start ups to the world's largest and most respected multinational biopharmaceutical companies. facility in Liverpool, UK that provides a full range of services for biopharmaceuticals and vaccines, including: cell line/strain development and banking, process development, cGMP manufacturing and analytical development for all significant biopharmaceutical product technologies - mammalian, microbial and viral.

Innovative therapeutics and biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate.

Food & Drug Analytical Services (FDAS) is a successful, independent, QC Laboratory, based in BioCity, Nottingham (UK). In October 2009 both the chemistry and microbiology cGMP facilities were reviewed and a successful audit was passed with another approval from the MHRA inspectors.

FDAS offers fast, customer driven QC analytical testing services to the pharmaceutical and heathcare industries, to a Global Market. FDAS performs a wide array of services including raw material and excipient testing, finished product analysis, product release, sterility, LAL, general microbiology and storage stability studies to pharmaceutical Manufacturing companies, and R&D facilities requiring cGMP..

FDAS is also particularly skilled in method development, validation and protocol design, and formulation.
Our experienced analytical team within our state of the art, GMP facility provide all the technical expertise needed to guarantee accurate, timely results that meet the requirements and rigours of any regulatory body (FDA/MHRA)

Fusion Antibodies is a world leader CMO in Antibody Sequencing; Antibody Engineering & Humanization and Expression and Purification of Pre-Clinical Grade Therapeutic & Diagnostic grade Proteins and cGMP scale up.

Antibody Cell line Sequencing
We can sequence from any antibody producing cell line. We have sequenced >500 antibodies from a variety of species with antibody variable domains sequenced from mouse, rat, bovine, human guinea pig, hamster, rabbits and human antibody secreting EBV cell lines.
Antibody Humanization
Fusion Antibodies have developed a technology for the rapid production of cell lines expressing fully humanized antibodies.
Antibody Engineering Services
ScFv / Fab Production: Fusion Antibodies have developed a technology to convert full monoclonal antibodies from a hybridoma cell line into single chain antibody fragments. These can be expressed in E. coli or CHO cells.
Antibody Chimerization: Fusion Antibodies have developed a technology for the rapid production of cell lines expressing full length recombinant antibodies.
Antibody Class Switching: Fusion Antibodies offers a service to switch IgM antibodies to IgG isotypes.
Expression and Purification of Pre-Clinical Grade Therapeutic & Diagnostic grade Proteins
We combine our bio-informatic and proteomic expertise to produce high quality recombinant protein to meet your requirements. Using FETâ„¢ Fusion can deliver your most challenging proteins. (FETâ„¢ is a multi parallel screening approach using a number of proprietary vector systems to speed up the production of your recombinant protein).

cGMP scale up
Fusion Antibodies can now deliver a full development package

HaloBioconsulting ia a healthcare advisory services firm focused on business alliances and management consulting for pharmaceutical and biotechnology companies and investors in healthcare. The company offers a broad portfolio of commercial and transactional services to the global pharmaceutical and biotechnology industries and the life-science investment sector.

Innova Biosciences Ltds core business is bioconjugation (antibody labeling) the joining of two molecules to form a hybrid conjugate™. Conjugates are used in hospital and research labs around the world; they also feature in consumer items such as pregnancy test kits (the conjugate is responsible for the blue line). Innova™s one-step conjugation method (Lightning-Link) massively simplifies the production of conjugates that are needed for research and immunodiagnostic applications. Innova also offers exclusive services for optimizing the performance of conjugates and developing more sensitive immunodiagnostic tests. Innova also sells several niche products to pharmaceutical research and development labs.

Isogenica specialises in the discovery of therapeutic and diagnostic peptides and proteins using its proprietary technology, CIS display. Established in 2000, and now based south of Cambridge UK at Chesterford Research Park, Isogenica has developed into a world leader in the field of peptide engineering. Isogenica has developed a powerful platform technology, known as CIS Display, that enables the discovery of novel peptide and protein therapeutics from vast pools, or libraries, of genes. CIS display enables the creation of libraries encoding upto 10^14 different clones and the selection of superior polypeptides from these. Isogenica works in partnership with pharmaceutical and biotechnology companies to rapidly select and engineer high quality peptide candidates using CIS display. CIS display is also available to license for scaffolds and larger proteins, such as single chain antibodies. Isogenica has partnered with over a dozen leading pharma and biotech companies in the discovery of novel peptides for therapeutic and non-therapeutic applications or for licenses. These include Amgen, Astra Zeneca, Centocor, GE Healthcare, Invitrogen, Johnson and Johnson, Pfizer, Smiths Detection Systems, UCB, Wyeth.

Lipoxen is a leading UK based biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a variety of important medical areas. Working with some of the largest pharmaceutical organisations in the world, Lipoxen provides leading edge expertise in the development of a whole new generation of drugs and vaccines.

BioAnaLab (Millipore) is a leading preclinical Contract Research Organisation providing specialty bioanalytical services for biological therapeutics. The core competency of BioAnaLab stems from our pioneering work and expertise in serving the increased need for specialist scientific and regulatory knowledge for biopharmaceutical analysis. We use ligand binding and cell based assays for immunogenicity (ADA), potency and stability testing, TK/PK and pharmacodynamic (PD/biomarker) analysis, immunophenotyping.

Moorfields Pharmaceuticals (a business unit of the globally renowned ophthalmology centre-of-excellence, Moorfields Eye Hospital, London) is an established specialty ophthalmology company marketing a broad range of licensed and unlicensed ophthalmology products, primarily in the UK and Ireland. The organization continues to expand its product range, and plans to launch at least 8 new licensed products in the next six months.

Moorfields Pharmaceuticals also provides pharmaceutical manufacturing services specializing in the manufacture and development of sterile liquidproducts, particularly for clinical trails supplies in ophthalmology.

Many new and existing drugs have enormous therapeutic potential, yet key physical properties that can drive efficacy are not ideal. Recent developments in solid form control, such as cocrystallisation, offer the possibility to solve such problems to create new and enhance existing drug products.

Nuformix's approach creates new drug forms that satisfy three key criteria:

• Physical properties are better tuned towards specific product requirements
• Protected by substance of matter patents
• Subject to low product approval and regulatory barriers

O2h, founded in 2003, now a part of the Piramal group of companies, is a specialist provider of medicinal chemistry and ADME services. Piramal Healthcare Solutions Ltd. employs 2,500 people globally, is publically listed and is one of India’s premier contract research and development service providers.

O2h’s 150+ employees work within its project management office in Cambridge, UK and its operations in Ahmedabad India. Our Indian base allows us to provide incredible speed/value compared to companies with operations in the West.

O2h operates from its 10,000 sq m state-of-the-art research facility with capacity for 28 dedicated 12 FH lab units. Aside from our core chemistry strengths, O2h also provide ADME services. Further information about our ADME services is available at http://o2h.com/InvitroADME.asp.

One Nucleus is an international membership organisation for life science companies. We are based in Cambridge and London UK, at the heart of Europe’s largest life science cluster. Our Vision is for One Nucleus and our members to be the top European life science network. We will achieve this by maximising the global competitiveness of our members. More than 500 members include pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

OET Ltd is a biotechnology company and centre of excellence for baculovirus based recombinant protein expression. OET provides protein expression products, services, consultancy and training to pharmaceutical and biotech companies and academic institutions. OET is also carrying out an extensive R & D programme.

Physiomics helps companies in the oncology field to determine optimal doses, schedules and combinations for pre-clinical animal studies.

During ten years of development in Oxford, our computational modelling approach has been validated with a number of customers. One top 10 pharma company in particular is now looking to include our method in their standard procedures.

Our offering provides the following key benefits:

(i)   Reduce the time taken to do proof of principle studies.
(ii)  Reduce the cost of a xenograft study programme (fewer experiments needed).
(iii) Provide regulatory agencies with a rationale for the design of a clinical study programme
(iv)  Improve the outcome of clinical studies (improving the likelihood of success in clinical studies using
an optimised dosing schedule).

In addition, our techniques can be used to:

(a) Unlock the potential of ‘sleeper drugs’ which have failed in clinical trials due to sub-optimal dosing or inappropriate schedules or combinations.
(b) Assess data packages for potential oncology in-licensing candidates.

Piramal Healthcare provides a wide range of API and drug product manufacturing, development and packaging services to meet clinical trial and commercial needs. Working with companies from top 20 pharma to small virtual pharma, Piramal supply product and services to all major pharmaceutical markets. We manufacture and package Phase I – III clinical trials materials through to commercial volumes for API and solid dosage drug product. Approval by the MHRA of our clinical trials packaging and distribution offering means that we can offer clients with products in development, a full service offering from one location. We have built a reputation for offering an excellent manufacturing capability and extremely efficient operating systems that deliver outstanding quality. Combined with our uncompromisingly professional attitude and uniquely flexible approach to meet deadlines, Piramal Healthcare endeavours to provide the solution to your out sourcing requirement.

PolyTherics is a biotechnology company that applies precision chemistry to develop protein and peptide-based drugs. The company has three technologies (TheraPEGTM, HIPEGTM and CyPEGTM) for site-specific attachment of PEG to proteins and peptides and offers to conduct feasibility studies on relevant partner molecules and to grant commercialisation licences for the technology.

Q Chip is using a novel approach to encapsulate therapeutic peptides in bioresorbable polymer microspheres for injection and sustained drug release (SR). We avoid the use of harsh solvents, high temperatures and shearing forces and achieve high API loading and microsphere monodispersity- two of the most important desirable features of any encapsulation approach, minimising production cost and enhancing syringe-ability, with controllable burst release. We have recently demonstrated successful sustained release over one month of octreotide, in a preclinical model. A small initial burst release was seen, followed by sustained and essentially zero order octreotide release over at least 35 days. Interestingly, there was no lag phase of octreotide release which might otherwise mandate additional daily injections to achieve therapeutic dosing.

We have had similar success with one and three month SR formulations of leuprolide and intend to go next to POC in man. Our octreotide and leuprolide SR formulations are available for licensing.

We use a similar benign approach to therapeutic protein encapsulation and are collaborating with Artes GmbH on the encapsulation of interferon alpha 2a for SR - targeting an improvement on the weekly shots of pegylated interferon currently taken by hep C sufferers.

Q Chip is developing novel technology platforms for the encapsulation of therapeutic peptides for sustained release (SR) and is committed to demonstrating its platforms' capabilities by producing POC data on SR depot formulations of two market leading therapeutic peptides, leuprolide and octreotide. These depot products will compete in the oncology market and in Q Chip's view represent de-risked opportunities for potential partners since both should be amenable to abbreviated regulatory procedures. We are willing to consider licensing our leuprolide and octreotide formulations and we are also interested in talking to potential partners with peptides in development - there is a clear opportunity to develop new sustained release formulations that may extend product patent life as well as enhancing patient compliance.

Randox Pharma Services offers a comprehensive range of technologies and solutions, allowing Pharma R&D and clinical trials to become more efficient, cost effective and safer.

Our award-winning Biochip Array Technology enables multiple biomarker results from a single sample and the Rx Series of clinical chemistry analysers, Quality Control sera, Diagnostic Reagents, Life Science products and Custom Assay Development service offers the highest quality and most comprehensive biomarker and companion diagnostic development package available.

Sareum is a drug discovery company focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer. The Company aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum has a portfolio of discovery-stage, targeted small molecule programmes which it would like to discuss with potential licence and/or collaborative partners.

Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR.

We help Scotland-based companies develop their international trade, offering a range of services to assist businesses who are entering foreign markets for the first time or expanding their overseas operations.

The Smerud Medical Research Group (SMERUD) is a clinical Contract Research Organisation (CRO) operating in the European area with offices in Denmark, Finland, Norway, Sweden, Poland, Russia, United Kingdom. Our activities are primarily focused on general drug development consulting to the biotech industries, and on executing clinical project management, monitoring of phase I-III studies, regulatory affairs, data management and medical writing projects. The company employs about 80 persons, of whom 65 are clinical research, regulatory or biostatistical professionals. We have been operating since 1993 with involvement in more than 600 clinical trials and more than 300 regulatory projects, in addition to approximately 100 projects related to data management, biostatistics and medical writing. Our international management team consists of senior professionals with many years of experience from the international pharmaceutical industry, academia as well as the consultancy business. The local country operational country units, each counting typically 5-18 CRAs, are headed by country managers, all with several years’ practical experience in clinical research. International project managers are based in key cities around Europe. Our company also funds internal clinical R&D projects including PhD progammes in collaboration with renowned medical faculties in our region.

Stabilitech is a thermal stabilisation company. Through use of the company's proprietary technology, it has demonstrated thermal stability of live and inactivated viral vaccines and biopharmaceuticals including antibodies and proteins. The company uses excipients which are proprietary in this setting, have been used in clinical settings at least and have relatively low cost of goods. The stabilisation procedures are robust with few additional steps which can readily be integrated into existing cGMP production processes. Stabilitech's technology addresses one of the major issues related to vaccines and other biopharmaceuticals, the need for cold chain, thereby reducing cost and, most importantly, protecting efficacy. Stabilitech's aim is to apply this novel and proprietary technology to the stabilisation of key vaccines and biopharmaceuticals through partnerships.

Sygnature Chemical Services, founded in 2004, is a leading United Kingdom-based provider of premium drug discovery services:

Sygnature operates a business whose primary focus is value creation for its clients. Working within the highly-complex, competitive and fast-paced pharmaceutical and biotech sectors in Europe and North America, Sygnature offers an exceptional approach to providing integrated medicinal chemistry-driven drug discovery services. Sygnature offers flexible resource, ‘cutting-edge’ technologies to maximise efficiency and drug discovery know-how from a modern, purpose-built R&D facility located in BioCity Nottingham. We have recruited a team of 38 scientists (mainly PhD qualified with 4-22 years pharmaceutical industry-experience) who have the ability to collaborate on an equal footing with clients. The Sygnature team contributes their drug discovery expertise and intellectual input into client projects. These include complete drug discovery programmes and hit finding, hit-to-lead and lead optimisation projects.

In summary, Sygnature offers a fully-enabled research department housing ‘state-of-the-art’ laboratories and technologies, and all the professional skills required to undertake the most demanding of drug discovery projects and drive them towards a successful outcome.

Theradex has been a niche provider of oncology drug development services for the past 26 years. The company was founded in 1982 providing oncology monitoring services to the National Cancer Institute in the US. In 1994, Theradex expanded into Europe in order to provide quality oncology drug development services on both a global and local level. Theradex has extensive experience in early phase oncology drug development as well as managing complex Phase 3 registration trials. The company maintains a strong focus on commitment to our clients. Theradex’s European headquarters are located in Crawley, West Sussex, and form part of the international Theradex group with headquarters in Princeton, NJ, USA. Theradex provides drug development services to a wide variety of clients including: the US government, US and European cooperative groups, pharmaceutical companies with headquarters throughout the world and biotech companies.

Warwick Effect Polymers (WEP) specialises in novel technologies to enhance biological therapeutics. WEP’s two proprietary biopolymer technologies are GlycoPol™ for drug targeting and delivery and PolyPEG® for extending the half-life of biologics. The Company’s objective is to develop partnerships with third parties to produce GlycoPol™ and PolyPEG® enhanced therapeutics and to license-out the technologies for specific molecules and/or applications.

GlycoPol™ is based on glycopolymers containing a diverse array of carbohydrates that offers the potential to target biological therapeutics, including proteins, peptides and oligonucleotides, to carbohydrate receptors on specific cells and tissues for cell uptake. PolyPEG® is a next generation PEGylation technology based on comb-shaped, PEG-containing polymers that not only have very low viscosity, allowing high concentrations to be administered to patients without difficulty, but also do not cause the tissue accumulation associated with conventional PEGs.